phrykt

UroGen Pharma Ltd. (URGN): who owns it and who trades it

As of Nov 16, 2026, URGN insiders reported 15 open-market sales worth $4.8M and no purchases in the last 12 months, with 27% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Schoenberg (Chief Medical Officer), with $4.5M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling UroGen Pharma

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns URGN

190 funds and institutions reported URGN shares worth $1.6B at the end of Q2 2026, about 91% of the company. The largest holder is Rtw Investments, LP with 9.3%.

Funds and institutions (13F) 91%Everyone else 9%

10 largest owners, by share of the company

Rtw Investments, LP9.3%
BlackRock, Inc.6.6%
Morgan Stanley5.3%
Kynam Capital Management, LP5.0%
Jefferies Financial Group Inc.4.5%
SG Americas Securities, LLC4.2%
American Century Companies Inc3.5%
Acorn Capital Advisors, LLC3.4%
California State Teachers Retirement System3.4%
Point72 Asset Management, L.P.3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Rtw Investments, LP4.54M9.33%$167MNo change
BlackRock, Inc.3.20M6.57%$118M+13%
Morgan Stanley2.58M5.29%$94.8M+1%
Kynam Capital Management, LP2.43M5.00%$89.6M+8%
Jefferies Financial Group Inc.2.20M4.51%$80.9MNo change
SG Americas Securities, LLC2.05M4.21%$75.5M+24%
American Century Companies Inc1.69M3.46%$62M+3%
Acorn Capital Advisors, LLC1.67M3.43%$61.6MNo change
California State Teachers Retirement System1.65M3.40%$44.9M+4169%
Point72 Asset Management, L.P.1.53M3.13%$56.1M–
Frontier Capital Management Co LLC1.51M3.10%$55.5M+15%
Opaleye Management Inc.1.44M2.96%$53M+1%
Silverarc Capital Management, LLC1.30M2.67%$47.9M-13%
Menora Mivtachim Holdings Ltd.1.15M2.37%$42.4MNo change
D. E. Shaw & Co., Inc.1.15M2.35%$42.2M+12%
State Street Corp1.00M2.06%$36.9M+15%
Mpm Bioimpact LLC933,4151.92%$34.3M-1%
Soleus Capital Management, L.P.829,8101.70%$30.5M+14%
Goldman Sachs Group Inc819,8341.68%$30.2M+37%
Migdal Insurance & Financial Holdings Ltd.770,9091.58%$28.4MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, URGN insiders reported $0 of open-market purchases and $4.8M of sales. 27% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$4.8M
15 trades, 3 people
Sales under a 10b5-1 plan
27%
Share of sale value
Latest trade
Oct 8, 2026
Filed Oct 9, 2026

Purchases and sales by month

$2.9M$2.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 8, 2026Chris DegnanCFOSale2,202$36.69$80.8KForm 4
Sep 8, 2026Mark SchoenbergChief Medical OfficerSale871$42.92$37.4KForm 4
Sep 8, 2026Jason Drew SmithGeneral CounselSale1,519$42.54$64.6KForm 4
Aug 20, 2026Mark SchoenbergChief Medical OfficerSale60,677$47.05$2.9MForm 4
Jul 9, 2026Mark SchoenbergChief Medical OfficerSale plan10,000$40.00$400KForm 4
Jun 22, 2026Mark SchoenbergChief Medical OfficerSale plan10,000$35.01$350KForm 4
Jun 8, 2026Mark SchoenbergChief Medical OfficerSale5,222$27.30$143KForm 4
May 8, 2026Mark SchoenbergChief Medical OfficerSale plan10,000$30.00$300KForm 4
Feb 3, 2026Jason Drew SmithGeneral CounselSale3,217$19.69$63.3KForm 4
Feb 3, 2026Jason Drew SmithGeneral CounselSale1,608$19.69$31.7KForm 4
Feb 3, 2026Jason Drew SmithGeneral CounselSale2,654$19.69$52.3KForm 4
Feb 3, 2026Mark SchoenbergChief Medical OfficerSale1,843$19.69$36.3KForm 4
Feb 3, 2026Mark SchoenbergChief Medical OfficerSale3,686$19.69$72.6KForm 4
Feb 3, 2026Mark SchoenbergChief Medical OfficerSale1,844$19.69$36.3KForm 4
Nov 19, 2025Mark SchoenbergChief Medical OfficerSale plan10,000$25.00$250KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark SchoenbergChief Medical Officer–$4.5MSep 8, 2026
Jason Drew SmithGeneral Counsel–$212KSep 8, 2026
Chris DegnanChief Financial Officer–$80.8KOct 8, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

URGN short interest

High short interest. 10.4% of URGN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 24%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.11M URGN shares were sold short, 10.4% of the shares outstanding, down 8.9% from the report before. At the average daily volume of 1.00M shares, buying them all back would take about 5.1 trading days (days to cover).

Shares short, % of all shares

10.4%May 15Oct 3016.9%

Days to cover

5.1May 15Oct 3012.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.11M10.41%-9%1.00M5.1
Oct 15, 20265.61M11.47%-28%1.14M4.9
Sep 30, 20267.77M15.89%+24%783,5479.9
Sep 15, 20266.25M12.78%No change681,7029.2
Aug 31, 20266.25M12.78%+22%919,4186.8
Aug 14, 20265.12M10.48%+12%1.07M4.8
Jul 31, 20264.59M9.39%-19%691,6346.6
Jul 15, 20265.69M11.68%-9%825,0846.9
Jun 30, 20266.22M12.76%-5%660,0949.4
Jun 15, 20266.56M13.46%-5%664,0539.9
May 29, 20266.92M14.21%+2%623,85911.1
May 15, 20266.76M13.88%-7%1.16M5.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

UroGen Pharma company events

UroGen Pharma filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 20, 2026AnnouncementUroGen Pharma Ltd., through its wholly owned subsidiary UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd., a company organized under the laws of Israel. Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. Jun 23, 2026LeadershipAt the Annual Meeting, the Company’s shareholders also approved (i) an amendment to the Company’s Amended and Restated Non-Employee Director and Officer Compensation Policy in relation to directors’ and officers’ insurance and (ii) an amendment to the Company’s 2017 Equity Incentive Plan (the “2017… Filing
  5. Jun 2, 2026AnnouncementUroGen Pharma Ltd. and UroGen Pharma Inc. (collectively, “the Company”) issued a press release announcing that the Company entered into a settlement and license agreement with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”) that resolves the patent litigation… Filing
  6. May 6, 2026ResultsReleased financial results. Filing
  7. Mar 2, 2026ResultsReleased financial results. Filing
  8. Mar 2, 2026AgreementUroGen Pharma Ltd., and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

UroGen Pharma financials

Famous investors that hold URGN

4 of the 50 well-known investors we track reported holding URGN in their latest 13F filing. The largest position is Israel Englander's, worth $10.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026268,902$10.9M0.0%+152%
Cathie Wood · ARK Investment ManagementQ3 202654,250$2.2M0.0%-47%
Ken Griffin · Citadel AdvisorsQ3 202635,665$1.4M0.0%+175%
Jim Simons · Renaissance TechnologiesQ3 202614,900$605K0.0%-79%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named URGN in the last 120 days.

FiledHolderFormStake
Nov 13, 2026The Toronto-Dominion Bank13G/A5.7%
Nov 13, 2026The Toronto-Dominion Bank13G/A5.7%
Oct 27, 2026BlackRock, Inc.13G/A6.3%
Oct 27, 2026BlackRock, Inc.13G/A6.3%

Questions about UroGen Pharma Ltd. (URGN) stock

Who owns the most URGN stock?

The largest reported owner of UroGen Pharma Ltd. (URGN) is Rtw Investments, LP, with 9.3% of the company. In total, 190 funds and institutions reported holding URGN at the end of Q2 2026, together about 91% of the shares. See the largest owners.

Are URGN insiders buying or selling?

In the last 12 months, URGN insiders reported no open-market purchases and 15 sales worth $4.8M. The latest trade was on Oct 8, 2026. See every trade.

What is the short interest in URGN?

As of Oct 30, 2026, 5.11M URGN shares were sold short, 10.4% of the shares outstanding, down 8.9% from the report before. At the average daily volume of 1.00M shares, buying them all back would take about 5.1 trading days (days to cover). See the history.

Which famous investors hold URGN?

4 of the 50 well-known investors we track reported URGN in their latest 13F filing, including Israel Englander, Cathie Wood, Ken Griffin. The largest position is worth $10.9M. See all holders.

Executive pay

UroGen Pharma's chief executive was paid a total of $4.3M for the year ended Dec 31, 2025, up 4% from $4.1M the year before. In the last 12 months, UroGen Pharma's executives and directors bought no stock on the open market and sold $4.8M.

Chief executive, total pay$4.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$11.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.